Literature DB >> 3192682

Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course.

D S Rao1, R J Wilson, M Kleerekoper, A M Parfitt.   

Abstract

We studied the natural history of primary hyperparathyroidism in patients in whom the disease was discovered fortuitously by multichannel biochemical screening and who were selected for conservative management because they were asymptomatic, had no renal stone disease or radiographic osteitis fibrosa, and had serum calcium values below 3.00 mmol/L, serum creatinine levels below 133 mumol/L, and forearm bone density not more than 2.5 SD below the mean expected for age, sex, and race. One hundred and seventy-four patients meeting these criteria were encountered during a 10-yr period, of whom 80 (mean age, 61 yr) had adequate follow-up; they did not differ significantly in any initial characteristic from the remaining 94 patients. These 80 patients were followed for 1-11 yr (mean, 46 months; median, 38 months), during which there was no change, mean or individual, in any index of PTH secretion or any of its biochemical effects and no decline in forearm bone density apart from that expected from increased age. There were 4 deaths from causes unrelated to hyperparathyroidism, and the overall death rate was not increased. The data suggest that no change occurred in either the number of parathyroid cells or secretory set-point, the 2 principal determinants of basal PTH secretion. This implies a biphasic course, with a short period of disease progression followed by a long period of disease stability. Our data support the decision to withhold surgical intervention in such patients, but to establish this as the correct policy for all asymptomatic patients will require a controlled clinical trial.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3192682     DOI: 10.1210/jcem-67-6-1294

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

Review 1.  Parathyroidectomy for asymptomatic primary hyperparathyroidism (PHPT): is it worth the risk?

Authors:  D S Rao
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

2.  Surgery for primary hyperparathyroidism.

Authors:  Henrik Ancher Sørensen
Journal:  BMJ       Date:  2002-10-12

Review 3.  Bone strength in primary hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

4.  Primary Hyperparathyroidism: A Tale of Two Cities Revisited - New York and Shanghai.

Authors:  Jian-Min Liu; Natalie E Cusano; Barbara C Silva; Lin Zhao; Xiao-Yan He; Bei Tao; Li-Hao Sun; Hong-Yan Zhao; Wen-Wei Fan; Megan E Romano; Guang Ning; John P Bilezikian
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

5.  Clinical value of calcium load test in differential diagnosis of different types of hyperparathyroidism.

Authors:  Xiaoxiao Zhu; Chang Shan; Qi Zhu; Lige Song; Yun Zhou; Jia Liu; Keqin Zhang
Journal:  Int J Clin Exp Med       Date:  2014-11-25

6.  Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism.

Authors:  D Han; S Trooskin; X Wang
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

Review 7.  Mild primary hyperparathyroidism: a literature review.

Authors:  Megan K Applewhite; David F Schneider
Journal:  Oncologist       Date:  2014-07-25

8.  Predictors of renal function in primary hyperparathyroidism.

Authors:  Marcella D Walker; Thomas Nickolas; Anna Kepley; James A Lee; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

9.  Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Authors:  Emanuela Traini; Rocco Bellantone; Serena Elisa Tempera; Salvatore Russo; Carmela De Crea; Celestino Pio Lombardi; Marco Raffaelli
Journal:  Langenbecks Arch Surg       Date:  2018-03-14       Impact factor: 3.445

Review 10.  Bone mineral content in calcium renal stone formers.

Authors:  A Trinchieri
Journal:  Urol Res       Date:  2005-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.